04/11/23 8:20 AMNasdaq : NVCN acquisitionShockwave Medical Completes Acquisition of Neovascvia NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previouslyRHEA-AIneutral
03/31/23 4:11 PMNasdaq : NVCN earningsNeovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Updatevia NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 millionRHEA-AInegative
03/06/23 5:37 PMNasdaq : NVCN acquisitionNeovasc Shareholders Approve Acquisition by Shockwave Medicalvia NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as definedRHEA-AIneutral
02/01/23 9:05 AMNasdaq : NVCN Neovasc Announces German Reimbursement Renewalvia NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) ( NASDAQ, TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medicalRHEA-AIvery positive
01/17/23 8:00 AMNasdaq : NVCN acquisitionShockwave Medical to Acquire NeovascNeovasc Inc. (" Neovasc" or the " Company") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a bindingRHEA-AIvery positive
11/28/22 4:45 PMNasdaq : NVCN clinical trialNeovasc Announces Progress on COSIRA-II Clinical Trial via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotalRHEA-AIvery positive
11/18/22 9:05 AMNasdaq : NVCN Neovasc Comments on European Heart Journal Publicationvia NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced that European Heart Journal - Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for RefractoryRHEA-AIneutral
11/10/22 4:05 PMNasdaq : NVCN earningsNeovasc Announces Third Quarter Financial Results and Provides Corporate Updatevia NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and aRHEA-AIneutral
11/08/22 9:05 AMNasdaq : NVCN Neovasc Reducer Obtains U.S. Outpatient ReimbursementNeovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a newRHEA-AIvery positive
10/27/22 9:00 AMNasdaq : NVCN conferencesearningsNeovasc to Report Third Quarter Financial Results on November 10, 2022Neovasc Inc. ( NASDAQ , TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark,RHEA-AIneutral